These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 22921157)

  • 1. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
    Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ
    Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
    Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
    BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
    Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M
    Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
    Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol.
    Rabban JT; Krasik E; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Dec; 33(12):1878-85. PubMed ID: 19898224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.
    Rabban JT; Crawford B; Chen LM; Powell CB; Zaloudek CJ
    Am J Surg Pathol; 2009 Jan; 33(1):111-9. PubMed ID: 18830124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
    Powell CB; Kenley E; Chen LM; Crawford B; McLennan J; Zaloudek C; Komaromy M; Beattie M; Ziegler J
    J Clin Oncol; 2005 Jan; 23(1):127-32. PubMed ID: 15625367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
    Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
    Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
    Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
    J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.
    Powell CB; Chen LM; McLennan J; Crawford B; Zaloudek C; Rabban JT; Moore DH; Ziegler J
    Int J Gynecol Cancer; 2011 Jul; 21(5):846-51. PubMed ID: 21670699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
    Cass I; Walts AE; Barbuto D; Lester J; Karlan B
    Gynecol Oncol; 2014 Sep; 134(3):492-7. PubMed ID: 25026639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status.
    George SH; Milea A; Shaw PA
    Clin Cancer Res; 2012 Nov; 18(22):6199-207. PubMed ID: 22967960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM
    Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
    Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
    JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.
    Cheng A; Li L; Wu M; Lang J
    Eur J Surg Oncol; 2020 Jan; 46(1):139-147. PubMed ID: 31521389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
    Blok F; Dasgupta S; Dinjens WNM; Roes EM; van Beekhuizen HJ; Ewing-Graham PC
    Gynecol Oncol; 2019 May; 153(2):326-334. PubMed ID: 30894273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk reducing surgery with peritoneal staging in BRCA1-2 mutation carriers. A prospective study.
    Marchetti C; Arcieri M; Vertechy L; Ergasti R; Russo G; Zannoni GF; Minucci A; Ercoli A; Scambia G; Fagotti A
    Eur J Surg Oncol; 2022 Dec; 48(12):2539-2544. PubMed ID: 35871032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
    Domchek SM; Friebel TM; Garber JE; Isaacs C; Matloff E; Eeles R; Evans DG; Rubinstein W; Singer CF; Rubin S; Lynch HT; Daly MB; Weitzel J; Ganz PA; Pichert G; Olopade OI; Tomlinson G; Tung N; Blum JL; Couch F; Rebbeck TR
    Breast Cancer Res Treat; 2010 Nov; 124(1):195-203. PubMed ID: 20180014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.